Allurion Technologies' Elipse (TM) Gastric Balloon Receives European Marketing Approval
World's First Procedureless Weight Loss Device Offers a New Treatment Option for Overweight and Obese Individuals
WELLESLEY, MA--(Marketwired - December 17, 2015) - Allurion Technologies announced today that its Elipseâ¢ Gastric Balloon has received a CE mark allowing sale of the product in the European Union.Â This is the company's first regulatory approval. Elipseâ¢ will initially be available in select leading weight loss centers in France, Italy and the United Kingdom.Â Elipseâ¢ is not yet approved by the FDA and is not available for sale in the United States.
Dr. Shantanu Gaur, Allurion's Co-Founder and Chief Scientific Officer, said that "excess weight often has a profound impact on health and quality of life including work, relationships and self-perception."Â However, of the nearly 2 billion overweight and obese adults worldwide, less than one percent have embraced currently available surgical and endoscopic options.Â Gaur continued, "weight loss therapies that require surgery, endoscopy, or anesthesia are often too invasive and can be too expensive for people who might otherwise greatly benefit from them."
"Our procedureless gastric balloon offers a simple, safe and effective alternative," said Dr. Samuel Levy, Allurion's Co-Founder and President.Â "Elipseâ¢ is a new way for overweight and obese individuals to take action."
Elipseâ¢ is Allurion's flagship product and is the world's first procedureless gastric balloon.Â Elipseâ¢ is made of thin, flexible polymer film and is delivered in a swallowable capsule, eliminating the need for surgery, endoscopy or anesthesia.Â It remains in the stomach for four months, after which it automatically empties and is excreted naturally. Elipseâ¢ will be provided by licensed physicians as part of a comprehensive weight loss program.
Allurion has studied Elipseâ¢ in individuals with a Body Mass Index (BMI) between 27 and 40 to assess its safety and its effects on body weight, metabolic parameters and quality of life.Â Interim results from a clinical study in 34 individuals were presented recently at ObesityWeek , the annual conference of the American Society for Metabolic and Bariatric Surgery and The Obesity Society . Findings included an average weight loss of 10 kilograms (22 pounds), with participants losing 37 percent of their excess weight and eight centimeters off their waist circumference over the four month treatment period.Â Participants also saw improvements in their triglycerides, hemoglobin A1c (HbA1c) and all aspects of quality of life.Â All balloons were safely and naturally excreted.
"Following six years of development, we are very excited to enter the next phase of our company's growth," said Jonathan Wecker, Allurion Technologies' Chief Executive Officer.Â "I am extremely proud of our team and thankful for the support of the many physicians and allied caregivers that have helped make Elipseâ¢ a reality.Â Following initial release in Europe, we expect to offer Elipseâ¢ in the Middle East and beyond in the months and years to come."
About Elipse â¢
Elipseâ¢ is a procedureless gastric balloon that is placed without surgery, endoscopy or anesthesia.Â It will be offered by physicians in conjunction with a medically supervised diet and exercise program.Â The device is swallowed in a capsule and filled with liquid through a thin delivery catheter, which is then detached.Â Elipseâ¢ remains in the stomach for four months after which the balloon opens, allowing it to empty and pass naturally from the body.Â Learn more and see an animation of Elipseâ¢ in action here .
About Allurion Technologies
Founded in 2009 by two Harvard Medical School students, Allurion Technologies is dedicated to developing less invasive treatments for overweight and obese individuals.Â The company's flagship product, Elipseâ¢, is a procedureless gastric balloon that works by filling the stomach, slowing digestion, and enabling portion reduction.Â Allurion is funded by private investors and the Massachusetts Life Sciences Center.Â Learn more about Elipseâ¢ and Allurion online at www.allurion.com or on Twitter @alluriontech .
Image Available: http://www.marketwire.com/library/MwGo/2015/12/15/11G075849/Images/Allurion-7_3_Blue-a99e534fad0f8e778fff2cf4d9c332a4.jpg
Embedded Video Available: https://www.youtube.com/watch?v=4E8j_zYLRH4&feature=youtu.be
Dr. Shantanu Gaur
Co-Founder and Chief Scientific Officer
+1 (781) 235-7050
Angus G. McQuilken
VP for Communications & Marketing
Massachusetts Life Sciences Center
+1 (617) 921-7749
Information om Marketwired
Følg pressemeddelelser fra Marketwired
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Marketwired
Bombardier Transportation28.5.2018 18:18 | pressemeddelelse
Bombardier Presents the New TRAXX DC3 Locomotive
Bombardier Transportation15.5.2018 02:51 | pressemeddelelse
Bombardier's Real-Time Passenger Load Display Software Solution Launches in Singapore
Bombardier Inc.3.5.2018 22:49 | pressemeddelelse
Bombardier Announces the Election of its Board of Directors, Pays Tribute to Former CEO and Chairman Laurent Beaudoin
Bombardier Inc.3.5.2018 14:04 | pressemeddelelse
Bombardier Reports First Quarter 2018 Results, Announces Sale of Downsview Property and plans for new Centre of Excellence for Global Aircraft
Bombardier Inc.2.5.2018 16:22 | pressemeddelelse
REMINDER/Media Advisory: Bombardier to Report its First Quarter 2018 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 3
Bombardier Inc.23.4.2018 22:11 | pressemeddelelse
Media Advisory: Bombardier to Report its First Quarter 2018 Financial Results and to Hold its Annual Meeting of Shareholders on Thursday, May 3
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum